Related Experiment Video
Updated: May 5, 2026

08:45
Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
13.6K
Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results From an
Filippo Trapani1,2, Giulio Viceconte3, Valentina Morena4
1Infectious Disease Unit, Department of Oncology and Hematology, Guglielmo da Saliceto Hospital, Piacenza, Italy.
Open Forum Infectious Diseases
|March 20, 2025
Abstract:
Outcomes are reported for 6 adults receiving rezafungin for chronic, hard-to-treat, invasive candidiasis (including Candida parapsilosis) during an early access program. Rezafungin was well tolerated and administered via once-weekly outpatient intravenous infusion for up to 39 weeks during the program, enabling hospital discharge and replacing daily antifungal infusions.

